The PI3K pathway: Clinical inhibition in chronic lymphocytic leukemia

Seminars in Oncology

Volumn 43, Issue 2, 2016, Pages 260-264

  Brown, Jennifer R ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

B cell receptor; CLL; Duvelisib; Idelalisib; PI3K; TGR 1202

Indexed keywords

DUVELISIB; IDELALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PILARALISIB; TGR 1202; UNCLASSIFIED DRUG; VOXTALISIB; ANTINEOPLASTIC AGENT; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ARTICLE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; DIARRHEA; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HYPERTRANSAMINASEMIA; LUNG INFECTION; LYMPHOCYTIC COLITIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MORTALITY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PURINES; QUINAZOLINONES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84961231332     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.02.004     Document Type: Review

References (35)

1. J.R. Brown The treatment of relapsed refractory chronic lymphocytic leukemia Hematology Am Soc Hematol Educ Program 2011 2011 110 118
2. M.S. Davids, and J.R. Brown Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia Leuk Lymphoma 53 2012 2362 2370
3. D Chantry, A Vojtek, A Kashishian, and et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes J Biol Chem 272 1997 19236 19241
4. B Vanhaesebroeck, S.J Leevers, G. Panayotou, and M.D. Waterfield Phosphoinositide 3-kinases: A conserved family of signal transducers Trends Biochem Sci 22 1997 267 272
5. B Vanhaesebroeck, K Ali, A Bilancio, B. Geering, and L.C. Foukas Signalling by PI3K isoforms: Insights from gene-targeted mice Trends Biochem Sci 30 2005 194 204
6. B Vanhaesebroeck, MJ Welham, K Kotani, and et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes Proc Natl Acad Sci USA 94 1997 4330 4335
7. K Ali, DR Soond, R Pineiro, and et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer Nature 510 2014 407 411
8. E Hirsch, VL Katanaev, C Garlanda, and et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation Science 287 2000 1049 1053
9. K Reif, K Okkenhaug, T Sasaki, and et al. Cutting edge: Differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing J Immunol 173 2004 2236 2240
10. JR Brown, JC Byrd, SE Coutre, and et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia Blood 123 2014 3390 3397
11. SE Herman, AL Gordon, AJ Wagner, and et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals Blood 116 2010 2078 2088
12. BJ Lannutti, SA Meadows, SE Herman, and et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
13. J Hoellenriegel, SA Meadows, M Sivina, and et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood 118 2011 3603 3612
14. JR Brown, M Hanna, B Tesar, and et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia Clin Cancer Res 18 2012 3791 3802
15. IW Flinn, BS Kahl, JP Leonard, and et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma Blood 123 2014 3406 3413
16. BS Kahl, SE Spurgeon, RR Furman, and et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) Blood 123 2014 3398 3405
17. JR Brown, J Byrd, R Furman, and et al. Preliminary Evidence of Clinical Activity in a Phase I Study of CAL-101, a Potent Selective Inhibitor of the p110 Delta Isoform of Phosphatidylinositol-3-Kinase, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Haematologica 94 2009 S88
18. RH Advani, JJ Buggy, JP Sharman, and et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 31 2013 88 94
19. BD Cheson, JC Byrd, KR Rai, and et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia J Clin Oncol 30 2012 2820 2822
20. M Hallek, BD Cheson, D Catovsky, and et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 2008 5446 5456
21. RR Furman, S De Vos, JP Leonard, and et al. A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia 4180 2013
22. Barrientos J, Coutre S, De Vos S, et al. Long-term follow-up of a phase 1b trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation. ASCO Meeting Abstracts 33, abstr 7011 (2015).
23. RR Furman, JP Sharman, SE Coutre, and et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 2014 997 1007
24. ®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors 330 2014
25. Jones J, Wach M, Robak T, et al. Results of a Phase 3 Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (IDELA) in Combination with Ofatumumab (OFA) for Previously Treated Chronic Lymphocytic Leukemia (CLL). ASCO Meeting Abstracts 33, abstr 7023 (2015).
26. O'Brien SM, Lamanna N, Kipp TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31, 7005 (2013).
27. SE Coutre, JC Barrientos, JR Brown, and et al. Management of adverse events associated with idelalisib treatment: Expert panel opinion Leuk Lymphoma 2015 1 8
28. Coutre S, Barrientos J, Brown JR, et al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. ASCO Meeting Abstracts 33, abstr e18030 (2015).
29. Horwitz SM, Flinn I, Patel MR, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed/refractory lymphoma. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31, 8518 (2013).
30. I Flinn, M Patel, BS Kahl, and et al. Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia Blood 122 2013 677
31. SM O'Brien, M Patel, BS Kahl, and et al. Duvelisib (IPI-145), a PI3K-d,g Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Blood 124 2014 3334
32. Patel MR, O'Brien SM, Faia K, et al. Early Clinical Activity and Pharmacodynamic Effects of Duvelisib, a PI3K-d,g Inhibitor, in Patients with Treatment-Naive CLL. ASCO Meeting Abstracts 33, 7074 (2014).
33. HA Burris, MR Patel, DM Brander, and et al. TGR-1202, a Novel Once Daily PI3Kd Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma Blood 124 2014 1984
34. Brown JR, Davids MS, Rodon J, et al. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma. Clinical Cancer Research. epub ahead of print (2015)
35. JR Brown, M Hamadani, J Arnason, and et al. SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study Blood 122 2013 86